Magnetic Affinity Nanoparticles for Bevacizumab Adsorption

BARREDO VACCHELLI, GABRIELA R.; GIUDICESSI, SILVANA L.; ALBERICIO, FERNANDO; CASCONE, OSVALDO; CAMPERI, SILVIA A.

Proceedings of the 36th European and the 12th International Peptide Symposium

Wiley

Año: 2022; p. 127 - 128

The vascular endothelial growth factor (VEGF) stimulates tumor angiogenesis by targeting its receptor (VEGFR) [1]. The IgG monoclonal antibody bevacizumab, produced in CHO cells, is used for cancer treatment due to its capability of targeting the endothelial growth factor A (VEGF-A) and inhibiting angiogenesis [2]. Bevacizumab purification step may account for as much as 70% of the total manufacturing cost because of the high purity necessary for its parenteral administration. Nowadays, its purification is achieved by protein A affinity chromatography (AC). However, protein A is a very expensive ligand and harsh elution conditions are required to recover bevacizumab from the AC column, which can damage the mAb as well as the protein A ligand [3].Recently, we have reported a short peptide contained in VEGF that binds to bevacizumab with high affinity and selectivity and demonstrated that this peptide bound to agarose can be used to purify bevacizumab at a lower cost and no harsh elution conditions [4]. However, conventional chromatography requires a previous clarification step to avoid column clogging.Unlike conventional chromatography, magnetic nanoparticle (MNP) purification allows the extraction of the target directly from the cell culture without needing clarification steps [5]. In this work, bevacizumab purification with MNP with a peptide ligand immobilized is assessed.